Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $28.6 million.

  • Amphastar Pharmaceuticals' Net Cash Flow rose 101785.16% to $28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.9 million, marking a year-over-year increase of 13058.81%. This contributed to the annual value of $7.5 million for FY2024, which is 16513.02% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Net Cash Flow stood at $28.6 million, which was up 101785.16% from $4.8 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Net Cash Flow peaked at $119.8 million during Q3 2023, and registered a low of -$126.3 million during Q4 2023.
  • Moreover, its 5-year median value for Net Cash Flow was $4.8 million (2025), whereas its average is $6.5 million.
  • Data for Amphastar Pharmaceuticals' Net Cash Flow shows a peak YoY increase of 145914.45% (in 2023) and a maximum YoY decrease of 1073845.49% (in 2023) over the last 5 years.
  • Over the past 5 years, Amphastar Pharmaceuticals' Net Cash Flow (Quarter) stood at $19.8 million in 2021, then crashed by 105.89% to -$1.2 million in 2022, then crashed by 10738.45% to -$126.3 million in 2023, then surged by 67.93% to -$40.5 million in 2024, then skyrocketed by 170.67% to $28.6 million in 2025.
  • Its last three reported values are $28.6 million in Q3 2025, $4.8 million for Q2 2025, and $31.1 million during Q1 2025.